The coronavirus disease (COVID-19) pandemic has changed the ways clinical trials are administered, said Reynold Panettieri, vice chancellor for Translational Medicine and Science at Rutgers. “In the past, clinical trials and clinical research were done usually in a clinical research unit,” Panettieri said. With this approach, participants would be evaluated in-person multiple times depending on the length of the clinical trial. Due to the COVID-19 pandemic, he said the whole design of clinical research had to be changed due to the potential for infection. To read the full story.